Search results
Author(s):
Eleftherios M Kallergis
,
Emmanuel N Simantirakis
Added:
1 month ago
Author(s):
Vivek Reddy
Added:
2 days ago
AHA 2025 - Dr Vivek Y Reddy (Icahn School of Medicine at Mount Sinai, New York, US) joins us to share findings from the PFA-SHAM study (NCT05717725) investigating pulsed field ablation (PFA) versus sham ablation to treat AF. Patients enrolled in the study underwent an electrophysiology study to ensure they had no concealed AV bypass tract or supraventricular tachycardia, and patients were then…
View more
Author(s):
Chao Jiang
,
Zhao Zixu
Added:
5 days ago
AHA Scientific Sessions 2025 – Dr Chao Jiang and Dr Zhao Zixu (Beijing Anzhen Hospital, CN) discuss the findings from the DARE-AF (NCT06433479) randomized clinical trial, investigating whether dapagliflozin reduces atrial fibrillation burden following catheter ablation in patients without diabetes or heart failure.This single-center, open-label trial enrolled 200 patients with persistent atrial…
View more
Author(s):
Riccardo Cappato
,
Rui Providencia
Added:
8 months ago
What updates do ECAS recommend for catheter ablation of atrial fibrillation?In this short interview, Prof Riccardo Cappato (IRCCS Humanitas Research Hospital, Milan, IT) and Prof Rui Providência (St Bartholomew's Hospital, London, UK) discuss new guidelines released by ECAS on catheter ablation for atrial fibrillation (AF). Prof Cappato and Prof Providência explain the need for an updated and…
View more
NHAF 2025
Start date:
Nov 13, 2025
End date:
Nov 13, 2025
Event
Author(s):
Renato D Lopes
Added:
1 year ago
ESC Congress 24 — AF screening with a wearable ECG device increases diagnosis by over 50% but did not significantly reduce hospitalisation rates for stroke.We are joined onsite at ESC Congress 2024 by Dr Renato Lopes (Duke University Medical Center, NC) to discuss the findings from the GUARD-AF Trial (NCT04126486, Bristol-Myers Squibb), which was designed to determine if screening for undiagnosed…
View more
Author(s):
Manesh R Patel
,
Harriette Van Spall
Added:
1 year ago
ESC Congress 2024 — OCEANIC-AF was halted early due to a lack of efficacy in 2023. Investigators shared details of the trial at ESC, comparing asundexian against apixaban in patients with atrial fibrillation at risk of stroke.Host Dr Harriette Van Spall (McMaster University, Hamilton, Canada) sits down with primary investigator Dr Manesh R Patel (Duke University Health System, USA) to discuss the…
View more
Author(s):
Else Sandset
,
Jesse Dawson
,
Urs Fischer
,
et al
Added:
2 years ago
Dr Else Sandset (Oslo University Hospital, NO) is joined by Prof Jesse Dawson (University of Glasgow, GB), Dr Urs Fischer (University Hospital Basel, CH) and Dr Masatoshi Koga (National Cerebral and Cardiovascular Center, JP) to discuss the findings from their recent paper on "Early versus Later Anticoagulation for Stroke with Atrial Fibrillation" published in the New England Journal of Medicine…
View more